Estée Lauder Launches Emerging Leaders Fund to Advance the Next Generation of Women Redefining Leadership
Estée Lauder, the flagship brand of The Estée Lauder Companies Inc., is proud to announce the launch of the Estée Lauder Emerging Leaders (ELEL) Fund, a charitable fund under The Estée Lauder Companies Charitable Foundation. The ELEL Fund’s mission is to redefine leadership by supporting a new generation of emerging women leaders and challenging the gender stereotypes of leadership. The Fund will support global organizations that provide opportunities for leadership development, cultivate supportive communities and advocate for emerging leaders who have a daring vision for change.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220504005425/en/
Estée Lauder has made an initial $1MM investment into the ELEL Fund which will support mission-aligned organizations. Vital Voices, a global nonprofit that invests in women leaders, has been selected as the inaugural program partner of the ELEL Fund, with the program commencing in July 2022. Additional grants by the ELEL Fund will be announced in the coming year.
Global Leadership and Gender Report by Estée Lauder
To gain a deeper understanding of perceptions of leadership and gender bias around the world, the Estée Lauder brand commissioned Glocalities, an international market research agency, for a global study of more than 5,700 men and women across 11 countries. The research revealed that whilst there are still prevalent gender biases and stereotypes when it comes to leadership, both men and women value the same qualities in a leader - reliability, integrity and dedication - which are not attached to gender. However, while leadership qualities such as strength and determination are equally valued by both men and women they are more strongly associated with men. The study reveals the roadblocks and solutions for advancing gender-inclusive leadership.
Estée Lauder’s Legacy
As one of the leading prestige beauty brands in the world, Estée Lauder continues to be inspired by its founder, Mrs. Estée Lauder, and her belief in a woman’s infinite possibilities. The ELEL Fund will reinforce the brand’s commitment to women’s advancement by addressing some of the gender-based biases uncovered in the research and shifting the perception of leadership.
“The 75-year legacy of the Estée Lauder brand shows what one visionary woman can achieve,” said Stéphane de La Faverie, Group President, The Estée Lauder Companies and Global Brand President, Estée Lauder & AERIN Beauty. “Through the work of the Estée Lauder Emerging Leaders Fund and its program partners, we will champion women to contribute and lead in their workplaces and communities. We want to redefine what it means to be a leader and what it takes to lead. We want to see more women like Mrs. Estée Lauder in the world.”
The VV Visionaries Leadership Program in partnership with the ELEL Fund
The Estée Lauder Emerging Leaders Fund selected Vital Voices, a global nonprofit that invests in women leaders who are taking on the world’s greatest challenges, as its first official program partner and grant recipient. With the shared mission of advancing women and redefining leadership, the ELEL Fund and Vital Voices have built a custom online and offline leadership development program for emerging leaders globally. Program participants will join the Vital Voices community of over 20,000 women across 184 countries, which includes Estée Lauder Global Changemaker, Amanda Gorman. Applications are now open for the first and second cohort and can be accessed at www.vitalvoices.org/program/visionaries.
“At Vital Voices we have seen that women lead differently, and that difference is precisely what our world needs,” said Alyse Nelson, Vital Voices President and CEO. “Our partnership with the Estée Lauder Emerging Leaders Fund will identify emerging leaders with a bold vision for positive change and provide them with the skills, network and resources they need to make that vision a reality.”
To learn more about the ELEL Fund, visit esteelauder.com.
Follow @esteelauder and #LeadYourWay hashtag to join the conversation.
About Estée Lauder
Estée Lauder is the flagship brand of The Estée Lauder Companies Inc. Founded by Estée Lauder, one of the world’s first female entrepreneurs, the brand today continues her legacy of creating innovative, sophisticated, high-performance skincare and makeup products and iconic fragrances – all infused with a deep understanding of women’s needs and desires. Today, Estée Lauder engages with customers in more than 150 countries and territories around the world and across dozens of touch points – from in-store to digital. And each of these relationships consistently reflects Estée’s powerful and authentic woman-to-woman point of view. Follow @esteelauder on Instagram, Facebook, Twitter, TikTok and YouTube.
About The Estée Lauder Emerging Leaders Fund
The Estée Lauder Emerging Leaders Fund is a charitable fund of The Estée Lauder Companies Charitable Foundation, a U.S. based charity incorporated and tax exempt in the United States of America.
About Vital Voices
Driven by the universal truth that women are the key to progress in their communities and that nations can’t move forward without women in leadership positions, Vital Voices Global Partnership has directly invested in more than 20,000 changemakers across 184 countries and territories over the last 24 years. It has provided early support for leaders who went on to become Nobel Peace Prize Laureates, U.S. Youth Poet Laureates, Prime Ministers, award-winning innovators, pioneering human rights defenders, and breakthrough social entrepreneurs, including Amanda Gorman, Malala Yousafzai, and more. Serving as a “venture catalyst,” the non-profit identifies leaders with a daring vision for change and partners with them to make that vision a reality. It provides connections, increased capacity, a peer network, financial support, skills training, and increased visibility for their work, which ranges from gender-based violence to the climate crisis, economic inequities. Follow @vitalvoices on Instagram, Facebook, Twitter, LinkedIn, and YouTube.
ELB-B
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220504005425/en/
Contact information
PR Contacts
Tara Connaughton, Estée Lauder, tconnaug@estee.com
Stephanie Katz, Estée Lauder, skatz@estee.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
